The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously showed that body mass index (BMI) correlates with increased SRD5A2 gene promoter methylation and decreased protein expression in men with symptomatic BPH. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether BMI is associated with the androgenic to estrogenic switch in human prostate tissue.
INTRODUCTION AND OBJECTIVES:
The steroid 5-a reductase type 2 (SRD5A2) is critical for prostatic development and growth. Strategies to block SRD5A2 using 5-a reductase inhibitors (5ARI) remain a mainstay in the treatment of benign prostatic hyperplasia (BPH). However, one-third of men are resistant to 5ARI therapies. We previously showed that body mass index (BMI) correlates with increased SRD5A2 gene promoter methylation and decreased protein expression in men with symptomatic BPH. We have demonstrated that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Here we wished to identify whether BMI is associated with the androgenic to estrogenic switch in human prostate tissue.
METHODS: Prostate specimens were collected from 35 patients who underwent transurethral resection of the prostate for symptomatic BPH at Massachusetts General Hospital. Medical records were reviewed to retrospectively collect clinical and pathological data. Patients were categorized by BMI as lean (less than 25 kg/m2), and overweight (25 kg/ m2 or greater). Use and duration of a-blockers and/or 5ARIs was assessed. Methylation of SRD5A2 promoter was assessed using Methylated CpG Island Recovery Assay (MIRA). Prostatic levels of testosterone, dihydrotestosterone and estradiol were measured by HPLC-MS.
RESULTS: We found that BMI was significantly correlated with methylation of SRD5A2 gene promoter (p<0.05) and absence of SRD5A2 protein expression. Higher BMI was associated with higher prostatic estradiol levels (p<0.05). IIEF-5 score, International Index of Erectile Function Questionnaire score, was negatively associated with BMI (p<0.05). Treatment with 5ARIs dramatically increased the level of prostate testosterone levels and testosterone/estradiol ratio in the prostate specimens (p<0.01, p¼0.01, respectively), and decreased the level of dihydrotestosterone (p<0.05).
CONCLUSIONS: Our study demonstrates for the first time that there is an androgenic to estrogenic switch in the prostate glands of overweight patients. Associated with body weight, somatic epigenetic silencing of SRD5A2 changes the prostatic hormonal milieu, and may modulate prostatic homeostasis and growth. Targeting the estrogenic signaling may serve as an effective treatment strategy in subset of overweight BPH patients. Clinical studies found that there was a small group of BPH patients 50 years old with severe LUTS that needed TURP to relieve LUTS. However, the causes of these clinical symptomatic BPH in men 50 years old remain unclear. Therefore, this study was designed to reveal the characteristic of these early progression BPH patients, and the mechanism was also investigated.
METHODS: Prostate tissues were obtained from 3 groups of BPH patients: 1. age50 years old who underwent TURP (Early-onset BPH) vs. 2. age-matched patients with bladder cancer who underwent cystoprostatectomy (age-matched control) vs. 3. age70 years old who underwent TURP for symptomatic BPH (Elderly BPH). The difference of histopathology between the three groups were examined by HE staining, Masson staining, and IHC for a-SMA, collagen I, CYP19 and GPER. MTT, Q-PCR and western blot were performed to examine the cell growth and fibrosis genes with the E2 or G1 treatment in WPMY-1 cells and prostate primary stromal cells (Prsc).
RESULTS: The results showed that the Early-onset BPH group had larger prostate volume than the age-matched control group, but much smaller than the Elderly BPH group (Table 1 ). The main characteristic of histopathology in early-onset BPH tissues appeared to be increased stromal components and increased prostatic stromal fibrosis (Fig.1) . IHC staining found these early-onset BPH tissues have higher expression of CYP19 and GPER in the prostate (Fig.1) . Importantly, E2 could promote the proliferation and fibrosis of prostatic stromal cells via activating GPER in WPMY-1 cells and Prsc ( Fig.2 and 3 ). Mechanism dissection revealed that E2 could function via GPER to modulate the EGFR/ERK to increase the prostatic stromal cells growth ( Fig.2 and 3) , and E2/GPER could induce the expression of HIF-1a which may promote the prostatic stromal fibrosis (Fig.4) .
CONCLUSIONS: Together, results from human specimens and in vitro cell lines' data concluded that the increased stromal components in prostate and prostatic fibrosis may play key roles for the development of the early-onset BPH that lead to the severe LUTS at a younger age than other men. Targeting this newly identified CYP19/Estrogen/GPER signaling may help us to develop a new therapy to better treat BPH patients at early age.
Source of Funding: This work was supported by National Natural Science Foundation of China (81370858, 81570683). Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e597
